Adicet Bio, Inc. (ACET)
Automate Your Wheel Strategy on ACET
With Tiblio's Option Bot, you can configure your own wheel strategy including ACET - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ACET
- Rev/Share 0.0714
- Book/Share 1.4643
- PB 0.4168
- Debt/Equity 0.1152
- CurrentRatio 7.4794
- ROIC -0.8477
- MktCap 50824482.0
- FreeCF/Share -1.1006
- PFCF -0.507
- PE -0.4686
- Debt/Assets 0.0942
- DivYield 0
- ROE -0.6848
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ACET | Guggenheim | -- | Buy | -- | $7 | Sept. 30, 2024 |
| Downgrade | ACET | H.C. Wainwright | Buy | Neutral | -- | -- | Sept. 11, 2024 |
News
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Published: November 28, 2025 by: Business Wire
Sentiment: Neutral
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 28, 2025. One individual was hired by Adicet in November 2025 and granted new hire non-qualified stock options to purchase 20,600 shares of Adicet's common stock with an exercise price of $0.65 per share, the closing price of.
Read More
Adicet Bio, Inc. - Special Call
Published: October 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Adicet Bio, Inc. - Special Call Company Participants Chen Schor - CEO, President & Director Julie Maltzman - Chief Medical Officer Blake Aftab - Senior VP & Chief Scientific Officer Conference Call Participants Jenna Li - Jefferies LLC, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Karina Rabayeva - Truist Securities, Inc., Research Division John Newman - Canaccord Genuity Corp., Research Division Robert Driscoll - Wedbush Securities Inc., Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Robert Burns - H.C. Wainwright & Co, LLC, Research Division …
Read More
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Adicet Bio (ACET) Upgraded to Buy: Here's Why
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About Adicet Bio, Inc. (ACET)
- IPO Date 2018-01-26
- Website https://www.adicetbio.com
- Industry Biotechnology
- CEO Chen Schor BA, CPA,
- Employees 152